METHODS: We conducted a search in PubMed limited to phase III randomized controlled trials (RCT) and corresponding long-term extension studies where the intervention was treatment with
ixekizumab in a population with PsA.
RESULTS: We identified 17 publications and 13 met inclusion criteria.
Injection site reactions (ISR) and
allergic reactions occurred in up to 25.3% and 6.2% with
ixekizumab and 4.5% and 1.85, respectively, with placebo. ISR occurred in 9.5-10.6% at 24 and 52 weeks with
ixekizumab versus 3.2-3.5% with
adalimumab (p < 0.01) in biologic-naïve PsA. Serious adverse events at 24 weeks occurred in 8.5% with
adalimumab versus 3.5% with
ixekizumab (p = 0.02), and at 52 weeks in 12.45 with
adalimumab and 4.25 with
ixekizumab (p < 0.01).
Ixekizumab had similar efficacy to
adalimumab across all PsA musculoskeletal, symptom and patient-reported outcome domains and surpassed
adalimumab in
psoriasis outcomes as well as all combined musculoskeletal and
psoriasis outcomes. The study subject population was overwhelmingly white, balanced men-women, BMI at the obese threshold, had on average 7-year PsA duration and 15-year
psoriasis duration. Disease activity was high with 7/66 swollen joints, 13/68 tender joints, 55% enthesitis, variable dactylitis (12-51%), and active
psoriasis in >92%.
CONCLUSION: